Diagnosis of Recurrent and Metastatic Disease Using F-18 Fluorodeoxyglucose-Positron Emission Tomography in Breast Cancer

Radiologic Clinics of North America

Volumn 45, Issue 4, 2007, Pages 659-667

  Eubank, William B ^a  

^a Puget Sound Veterans Administration Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC ACCURACY; DRUG UPTAKE; HUMAN; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 34547774271     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2007.05.005     Document Type: Review

References (64)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer Statistics, 2000. CA Cancer J Clin 50 1 (2000) 7-33
2. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17 3B (1997) 1687-1692
3. Moon D.H., Maddahi J., Silverman D.H.S., et al. Accuracy of whole-body [fluorine-18]-FDG-PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39 3 (1998) 431-435
4. Lonneux M., Borbath I., Berliere M., et al. The place of whole-body FDG-PET for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3 2 (2000) 45-49
5. Kim T.S., Moon W.K., Lee D.S., et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 25 7 (2001) 829-834
6. Lin W.Y., Tsai S.C., Cheng K.Y., et al. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer-Taiwanese experiences. Cancer Invest 20 5-6 (2002) 725-729
7. Liu C.S., Shen Y.Y., Lin C.C., et al. Clinical impact of [18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32 7 (2002) 244-247
8. Suarez M., Perez-Castejon M.J., Jimenez A., et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46 2 (2002) 113-121
9. Gallowitsch H.J., Kresnik E., Gasser J., et al. [18F]- fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38 5 (2003) 250-256
10. Siggelkow W., Zimny M., Faridi A., et al. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 23 2C (2003) 1859-1868
11. Kamel E.M., Wyss M.T., Fehr M.K., et al. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129 3 (2003) 147-153
12. Eubank W.B., Mankoff D.A., Vesselle H.J., et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG-PET. Radiographics 22 1 (2002) 5-17
13. Eubank W.B., Mankoff D.A., Schmiedl U.P., et al. Imaging of oncologic patients: benefit of combined CT and [F-18]-fluorodeoxyglucose positron emission tomogoraphy scan interpretation in the diagnosis of malignancy. Am J Roentgenol 171 4 (1998) 1103-1110
14. 18FDG-PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 42 9 (2001) 1334-1337
15. Eubank W.B., Mankoff D.A., Bhattacharya M., et al. Impact of [F-18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. Am J Roentgenol 83 2 (2004) 479-486
16. Hortobagyi G.N. Developments in chemotherapy of breast cancer. Cancer 88 Suppl 12 (2000) 3073-3079
17. Taghian A., Jeong J., Mamounas E., et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 22 21 (2004) 4247-4254
18. Schwaibold F., Fowble B.L., Solin L.J., et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 21 2 (1991) 299-310
19. Probstfeld M.R., and O'Connell T.X. Treatment of locally recurrent breast carcinoma. Arch Surg 124 10 (1989) 1127-1129 [discussion: 1130]
20. Valagussa P., Bonadonna G., and Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41 3 (1978) 1170-1178
21. Kamby C., Rose C., Ejlertsen B., et al. Stage and pattern of metastases in patients with breast cancer. Eur J Cancer Clin Oncol 23 12 (1987) 1925-1934
22. Schmolling J., Maus B., Rezek D., et al. Breast preservation versus mastectomy-recurrence and survival rates of primary breast cancer patients treated at the UFK Bonn. Eur J Gynaecol Oncol 18 1 (1997) 29-33
23. Huston T.L., and Simmons R.M. Locally recurrent breast cancer after conservation therapy. Am J Surg 189 2 (2005) 229-235
24. Leborgne F., Leborgne J.H., Ortega B., et al. Breast conservation treatment of early stage breast cancer: patterns of failure. Int J Radiat Oncol Biol Phys 31 4 (1995) 765-775
25. Katz A., Strom E.A., Buchholz T.A., et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18 15 (2000) 2817-2827
26. Aristei C., Marsella A.R., Chionne F., et al. Regional node failure in patients with four or more positive lymph nodes submitted to conservative surgery followed by radiotherapy to the breast. Am J Clin Oncol 23 3 (2000) 217-221
27. Nikkanen T.A. Recurrence of breast cancer. A retrospective study of 569 cases in clinical Stages I-III. Acta Chir Scand 147 4 (1981) 239-245
28. Kiricuta I.C., Willner J., Kolbl O., et al. The prognostic significance of the supraclavicular lymph node metastases in breast cancer patients. Int J Radiat Oncol Biol Phys 28 2 (1994) 387-393
29. Iyer R.B., Fenstermacher M.J., and Libshitz H.I. MR imaging of the treated brachial plexus. Am J Roentgenol 167 1 (1996) 225-229
30. Bagley F.H., Walsh J.W., Cady B., et al. Carcinomatous versus radiation-induced brachial plexus neuropathy in breast cancer. Cancer 41 6 (1978) 2154-2157
31. Toi M., Tanaka S., Bando M., et al. Outcome of surgical resection for chest wall recurrence in breast cancer patients. J Surg Oncol 37 1 (1997) 853-863
32. Hathaway C.L., Rand R.P., Moe R., et al. Salvage surgery for locally advanced and locally recurrent breast cancer. Arch Surg 129 6 (1994) 582-587
33. Hathaway P.B., Mankoff D.A., Maravilla K.R., et al. The value of combined FDG-PET and magnetic resonance imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 210 3 (1998) 807-814
34. Ahmad A., Barrington S., Maisey M., et al. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 79 3-4 (1999) 478-482
35. Byrd D.R., Dunnwald L.K., Mankoff D.A., et al. Internal mammary lymph node drainage patterns with breast cancer documented by breast lymphoscintigraphy. J Surg Oncol 8 3 (2001) 234-240
36. Donegan W.L. The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer 39 2 (1977) 533-538
37. Veronesi U., Cascinelli N., Greco M., et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 202 6 (1985) 702-707
38. Lacour J., Le M., Caceres E., et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 51 10 (1983) 1941-1943
39. Noguchi M., Ohta N., Thomas M., et al. Risk of internal mammary lymph node metastases and its prognostic value in breast cancer patients. J Surg Oncol 52 1 (1993) 26-30
40. Veronesi U., Marubini E., Del Vecchio M., et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87 1 (1995) 19-27
41. Cody III H.S., and Urban J.A. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 2 1 (1995) 32-37
42. Freedman G.M., Fowble B.L., Nicolaou N., et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist?. Int J Radiat Oncol Biol Phys 46 4 (2000) 805-814
43. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97 2 (2005) 116-125
44. Schirrmeister H., Kuhn T., Guhlmann A., et al. [F-18]-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28 3 (2001) 351-358
45. Greco M., Crippa F., Agresti R., et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 93 8 (2001) 630-635
46. Bellon J.R., Livingston R.B., Eubank W.B., et al. Evaluation of the internal mammary (IM) lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27 4 (2004) 407-410
47. Bernstein V., Jones A., Mankoff D.A., et al. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission (FDG-PET) in medial hemisphere breast cancer. [abstract]. J Nucl Med 41 (2000) 289P
48. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16 6 (1998) 2142-2149
49. Scott W.J., Gobar L.S., Terry J.D., et al. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 111 3 (1996) 642-648
50. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19 15 (2001) 3516-3523
51. Coleman R.E., and Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 55 1 (1987) 61-66
52. Nielsen O.S., Munro A.J., and Tannock I.F. Bone metastases: pathophysiology and management policy. J Clin Oncol 9 3 (1991) 509-524
53. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22 8 (2001) 875-879
54. Yang S.N., Liang J.A., Lin F.J., et al. Comparing whole body [18F]-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128 6 (2002) 325-328
55. Kao C.H., Hsieh J.F., Tsai S.C., et al. Comparison and discrepancy of [18F]-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20 3B (2000) 2189-2192
56. 18FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 10 (1998) 3375-3379
57. Uematsu T., Yuen S., Yukisawa S., et al. Comparison of FDG-PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol 84 4 (2005) 1266-1273
58. Schirrmeister H., Guhlmann A., Kotzerke J., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17 8 (1999) 2381-2389
59. Schirrmeister H., Glatting G., Hetzel J., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and [18]F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42 12 (2001) 1800-1804
60. 18F-FDG-PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 43 3 (2002) 325-329
61. Pelosi E., Messa C., Sironi S., et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31 7 (2004) 932-939
62. Buck A.K., Wahl A., Eicher U., et al. Combined morphological and functional imaging with FDG-PET/CT for restaging breast cancer-impact on patient management. [abstract]. J Nucl Med 44 (2003) 78P
63. Tatsumi M., Cohade C., Mourtzikos K.A., et al. Initial experience with FDG-PET-CT in the evaluation of breast cancer. [abstract]. J Nucl Med 44 (2003) 394P
64. Ciernik F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57 3 (2003) 853-863